Develops an antibody treatment candidate for patients with severe asthma, chronic rhinosinusitis with nasal polyps, and COPD.
10-K for FY2025, filed Mar 26, 2026
Maruho reimburses the company for research and development work and drug-supply costs in Japan; revenue is earned as the work progresses.
10-K for FY2025, filed Mar 26, 2026
$2.9M
10-K for FY2025, filed Mar 26, 2026
$2.9M ↗
Maruho holds a license and reimburses Upstream Bio for research and development work and drug supply in Japan; Upstream Bio conducts those activities.
10-K for FY2025, filed Mar 26, 2026
No. It lost $143.4M in FY2025.
Competes with Genentech, Novartis, Sanofi, Regeneron, GSK, AstraZeneca, and Amgen
10-K for FY2025, filed Mar 26, 2026Existing therapeutics for asthma include controller medications, reliever medications and more recently, biologics from Genentech, Inc.…View ↗
Loading...